TYK2 and psoriasis: Indeed, BMS‐986165 (Deucravacitinib) is a selective potent oral TYK2 inhibitor currently used for psoriasis treatment [54], and two other TYK2 inhibitors (TAK‐279, VTX958) are under development for psoriasis treatment.